SOPHiA GENETICS SA ( SOPH ) NASDAQ Global Select

Cena: 2.99 ( -1.64% )

Aktualizacja 07-03 22:00
NASDAQ Global Select
Branża: Medical - Healthcare Information Services

Notowania:


Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Healthcare Information Services
Zatrudnienie: 430
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 72%
Ilość akcji: 65 032 799
Debiut giełdowy: 2021-07-23
WWW: https://www.sophiagenetics.com
CEO: Dr. Jurgi Camblong M.B.A., Ph.D.
Adres: Rue du Centre 172
Siedziba: 1025 Saint-Sulpice
ISIN: CH1125843347
Opis firmy:

Sophia Genetics SA działa jako firma zajmująca się technologią opieki zdrowotnej. Firma oferuje platformę Sophia DDM, oparte na chmurze platforma oprogramowania jako usługi do analizy danych i generowania spostrzeżeń z multimodalnych zestawów danych i modalności diagnostycznych. Platforma Sophia DDM oraz powiązane rozwiązania, produkty i usługi są wykorzystywane przez szpital, laboratorium i biofarma na całym świecie. Sophia Genetics SA została zarejestrowana w 2011 roku i ma siedzibę w Saint-Sulpice w Szwajcarii.

Wskaźniki finansowe
Kapitalizacja (USD) 199 824 989
Aktywa: 177 608 000
Cena: 2.99
Wskaźnik Altman Z-Score: -1.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -3.0
Ilość akcji w obrocie: 72%
Średni wolumen: 76 350
Ilość akcji 66 831 100
Wskaźniki finansowe
Przychody TTM 64 488 000
Zobowiązania: 64 101 000
Przedział 52 tyg.: 2.58 - 4.92
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -1.0
P/E branży: 32.4
Beta: 1.032
Raport okresowy: 2025-08-04
WWW: https://www.sophiagenetics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Jurgi Camblong M.B.A., Ph.D. Co-Founder, Chief Executive Officer & Director 1 105 380 1978
Dr. Zhenyu Xu Ph.D. Executive Vice President & Chief Scientific Officer 0 1983
Dr. Philippe Menu M.B.A., M.D., Ph.D. Executive Vice President, Chief Medical Officer & Chief Product Officer 0 1982
Mr. Daan van Well L.L.M., M.B.A. Executive Vice President, Chief Legal & Compliance Officer 0 1975
Katherine Bailon Vice President of Investor Relations 0 0
Mr. Kevin Puylaert Vice President & MD of EMEA 0 0
Mr. Abhimanyu Verma Senior Vice President & Chief Technology Officer 0 0
Mr. Ross Jordan Muken B.Sc. Executive Vice President, Chief Financial Officer & Chief Operating Officer 0 1981
Ms. Manuela Da Silva Valente B.A. Executive Vice President & Chief People Officer 0 1971
Wiadomości dla SOPHiA GENETICS SA
Tytuł Treść Źródło Aktualizacja Link
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call. seekingalpha.com 2025-05-10 07:05:48 Czytaj oryginał (ang.)
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago. zacks.com 2025-05-06 12:55:34 Czytaj oryginał (ang.)
SOPHiA GENETICS Reports First Quarter 2025 Results BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter  2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024 begins to ramp," said Jurgi Camblong, PhD. prnewswire.com 2025-05-06 10:45:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025. prnewswire.com 2025-04-28 16:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. prnewswire.com 2025-04-22 12:00:00 Czytaj oryginał (ang.)
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md. prnewswire.com 2025-04-08 06:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-03-21 15:01:09 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data. prnewswire.com 2025-03-18 11:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today. seekingalpha.com 2025-03-04 16:32:52 Czytaj oryginał (ang.)
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago. zacks.com 2025-03-04 10:55:27 Czytaj oryginał (ang.)
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue  Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectively Operating loss was $17.4 million on a reported basis and $10.2 million on an adjusted basis, representing year-over-year improvements of 8% and 23%, respectively Full Year 2024 Financial Highlights Revenue was $65.2 million, up 4% year-over-year or 5% on a constant currency basis excluding COVID-19-related revenue  Gross margin was 67.4% on a reported basis and 72.8% on an adjusted basis, compared to 68.8% and 72.2% in the prior year period, respectively Operating loss was $66.6 million on a reported basis and $44.8 million on an adjusted basis, representing year-over-year improvements of 11% and 20%, respectively "We continued driving widespread adoption of SOPHiA DDM™ in 2024, achieving a record number of analyses, major new customers wins, and healthy volume growth during the year, despite BioPharma headwinds which impacted overall performance and resulted in softer revenue growth than we would have liked," said Jurgi Camblong, PhD. prnewswire.com 2025-03-04 08:45:00 Czytaj oryginał (ang.)
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications. prnewswire.com 2025-02-24 06:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 BOSTON and ROLLE, Switzerland , Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. prnewswire.com 2025-02-18 10:30:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland , Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. prnewswire.com 2025-01-28 10:46:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024 Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency. prnewswire.com 2024-11-21 07:30:00 Czytaj oryginał (ang.)
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today. seekingalpha.com 2024-11-05 16:46:04 Czytaj oryginał (ang.)
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. prnewswire.com 2024-11-05 08:32:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Reports Third Quarter 2024 Results Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter  2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectively Operating loss was $15.4 million on a reported basis and $10.6 million on an adjusted basis, representing year-over-year improvements of 7.1% and 10.4%, respectively Cash burn was $9.6 million, representing a year-over-year improvement of 39.1% The company reiterates full-year guidance, including revenue between $65 million and $67 million, adjusted gross margin of 72.0% to 72.5%, and adjusted operating loss between $45 million and $50 million "Record analysis volume drove a reacceleration of Clinical growth across most key geographies in Q3, with volume increasing 16% year-over-year, offset by expected softness in BioPharma," said Jurgi Camblong, PhD. prnewswire.com 2024-11-05 08:30:00 Czytaj oryginał (ang.)
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024 BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. prnewswire.com 2024-10-22 10:45:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. prnewswire.com 2024-09-14 13:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024 Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. prnewswire.com 2024-09-12 11:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024 The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. prnewswire.com 2024-09-12 08:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. prnewswire.com 2024-09-10 14:16:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. prnewswire.com 2024-09-05 12:30:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024 New generation of SOPHiA DDM TM  integrates latest  advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDMTM Platform. prnewswire.com 2024-09-04 10:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen FutureHealth Conference in early September. Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 22nd Annual Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024, at 1:50 p.m. prnewswire.com 2024-08-28 17:30:00 Czytaj oryginał (ang.)
SOPHiA DDM™ Platform Certified Under IVDR Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM™ Platform is now CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR). IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers throughout the European Union and other markets recognizing this certification to use the SOPHiA DDM™ Platform to support patient diagnostics. prnewswire.com 2024-08-14 07:00:00 Czytaj oryginał (ang.)
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2024-08-12 14:36:44 Czytaj oryginał (ang.)
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-08-09 17:01:20 Czytaj oryginał (ang.)
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. zacks.com 2024-08-06 12:56:18 Czytaj oryginał (ang.)
SOPHiA GENETICS Reports Second Quarter 2024 Results Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter  2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-over-year Gross margins were 68.2% on a reported basis and 73.2% on an adjusted basis, up from 66.7% and 70.0% in the prior year period, respectively Operating loss was $15.0 million on a reported basis and $9.9 million on an adjusted basis, representing year-over-year improvements of 25% and 32%, respectively 2024 Financial Outlook Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to FY 2023 Adjusted gross margin is now expected to be between 72.0% to 72.5%, compared to 72.2% in FY 2023 Adjusted operating loss guidance remains unchanged and is expected to be between $45M and $50M, compared to $55.9 million in FY 2023 "We delivered another quarter of strong forward-looking indicators and continued bottom-line improvements in Q2, despite facing macro-related headwinds in BioPharma and EMEA which offset outsized performance in the U.S.," said Jurgi Camblong, PhD. prnewswire.com 2024-08-06 10:45:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™ The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. prnewswire.com 2024-07-29 14:30:00 Czytaj oryginał (ang.)
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. prnewswire.com 2024-07-24 15:59:00 Czytaj oryginał (ang.)
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. prnewswire.com 2024-07-24 14:00:00 Czytaj oryginał (ang.)